Search results
Results from the WOW.Com Content Network
Coricidin, Coricidin 'D' (decongestant), or Coricidin HBP (for high blood pressure), is the name of an over-the-counter cough and cold drug containing dextromethorphan (a cough suppressant) and chlorpheniramine maleate (an antihistamine). [1] Introduced by Schering-Plough in 1949 as one of the first antihistamines, it is now owned by Bayer.
Hyoscine butylbromide, also known as scopolamine butylbromide [4] and sold under the brandname Buscopan among others, [5] is an anticholinergic medication used to treat abdominal pain, esophageal spasms, bladder spasms, biliary colic, [6] and renal colic.
[citation needed] In 2016, it was one of the biggest selling branded over-the-counter medications sold in Great Britain, with sales of £34.4 million. [37] The effectiveness of phenylephrine by mouth as a nasal decongestant is questionable. [38] Gee's Linctus is a cough medicine which contains opium tincture. [39]
Codeine is used to treat mild to moderate pain. [4] It is commonly used to treat post-surgical dental pain. [13]Weak evidence indicates that it is useful in cancer pain, but it may have increased adverse effects, especially constipation, compared to other opioids. [14]
CVS Health is pulling from its shelves some cough-and-cold treatments that contain an ingredient that has been deemed ineffective by doctors and researchers. The drug store chain said it will ...
pentoxyfylline – xanthine derivative used in as an antiinflammatory drug and in the prevention of endotoxemia; pergolide – dopamine receptor agonist used for the treatment of pituitary pars intermedia dysfunction in horses; phenobarbital – anti-convulsant used for seizures; phenylbutazone – nonsteroidal anti-inflammatory drug (NSAID)
Ambroxol is a drug that breaks up phlegm, used in the treatment of respiratory diseases associated with viscid or excessive mucus. Ambroxol is often administered as an active ingredient in cough syrup. It was patented in 1966 and came into medical use in 1979. [1]
The FDA's decision gives some breathing room to rival GSK's chronic cough treatment camlipixant, which is in late-stage development with anticipated regulatory approval and launch in 2026.